Mark Blumenkranz's guest appearances

Mark Blumenkranz

Straight From The Cutter's Mouth: A Retina Podcast

OIS Podcast

Mark Humayun

Emmett Cunningham

Thomas Albini

Daniel Chao

Steve Charles

Stephen Russell

Adrienne Scott

Brent Saunders

Sarah Read

Jim Dahle

Emily Silverman

David Muller

Andrew Chang

Paul Chan

David Tanzer

OwlTail

Eye care innovator extraordinaire Mark Blumenkranz joins the podcast to preview the April 8 Forum on Laser-Based Imaging workshop. In this interview, Blumenkranz explains why eye care professionals of all types – ophthalmologists and optometrists – should plan on attending. We also talk about one of the more recent investments by Blumenkranz’s venture firm, Lagunitas Biosciences. Go to this link for more information about the workshop.

<p>Eye care innovator extraordinaire Mark Blumenkranz joins the podcast to preview the April 8 Forum on Laser-Based Imaging workshop. In this interview, Blumenkranz explains why eye care professionals of all types – ophthalmologists and optometrists – should plan on attending. We also talk about one of the more recent investments by Blumenkranz’s venture firm, Lagunitas Biosciences. Go to <a href="https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm628801.htm" rel="nofollow" target="_blank">this link</a> for more information about the workshop.</p>

Mark Blumenkranz Previews Upcoming Laser-Based Imaging Workshop, Updates on Big Data, Digital Tech

Episode 96: Dr. Mark Blumenkranz discusses working with industry, academic chair selection and work demands, and pattern-scanning laser

Accomplished ophthalmologist Mark Blumenkranz, MD, moved early into the Digital Health space by co-founding Digisight, one of the more advanced efforts in ophthalmology. Six years, later, Dr. Blumenkranz still sees enormous opportunity so he’s working with the FDA and top clinical societies to hold a one-day workshop for physicians, investors, and entrepreneurs interested in learning how Digital Health fits into ophthalmology.

Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop